Clinical Trials Browser

Phase 1/2 × pembrolizumab × Plasma cell × Clear all

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03267888 2024-09-04

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT03848845 2024-04-09

DREAMM 4

Phase 1/2 Completed

41 enrolled 57 charts

Plasma cell

Multiple Myeloma

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT03191981 2017-08-24

MUKfourteen

Phase 1/2 Withdrawn

Plasma cell

Multiple Myeloma

Clinical Trials

KEYNOTE145

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

DREAMM 4

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

MUKfourteen